دورية أكاديمية
Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis
العنوان: | Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis |
---|---|
المؤلفون: | Yao Zhang, Huiting Li, Bo Yu, Si Sun, Zhihuang Hu, Xianghua Wu, Yang Zhang, Bin Li, Yawei Zhang, Jiaqing Xiang, Jialei Wang, Hui Yu |
المصدر: | Thoracic Cancer, Vol 15, Iss 13, Pp 1072-1081 (2024) |
بيانات النشر: | Wiley, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | efficacy, locally advanced esophageal squamous cell carcinoma, neoadjuvant chemoimmunotherapy, safety, survival outcomes, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | Abstract Background Neoadjuvant chemoimmunotherapy (NCIT) for locally advanced esophageal squamous cell carcinoma (ESCC) is supported by increasing data, but the sample size is limited, and the findings are not completely consistent. We conducted a real‐world study and a meta‐analysis to evaluate the efficacy and safety of NCIT in locally advanced ESCC. Methods We retrospectively assessed the outcomes of patients with locally advanced ESCC who completed NICT and subsequent esophagectomy at our hospital between January 2019 and December 2022, including pathological complete response (pCR) rate, major pathological response (MPR) rate, 1‐, 2‐, and 3‐year overall survival (OS) rates, disease control rate (DCR), objective response rate (ORR), 1‐year recurrence rate, R0 resection rate and adverse events. Moreover, a meta‐analysis of 27 published literatures was also conducted for comparison. Results In the analysis, 128 patients were studied, with 25% achieving pCR, 46.1% MPR, and 99.2% R0 resection. The 1‐, 2‐, and 3‐year OS rates were 91.41% (95% CI: 85.15%–95.63%), 75.00% (95% CI: 66.58%–82.23%) and 64.84% (95% CI: 55.91%–73.07%).ORR and DCR were 31.2% (95% CI: 23.31–39.99) and 64.1% (95% CI: 55.15%–72.38%), and the 1‐year recurrence rate was 26.7% (95% CI: 22.5%–38.1%). Treatment‐related events occurred in 96.1% but were acceptable. In a meta‐analysis of 27 studies with 1734 patients, pooled rates for pCR, MPR, ORR, DCR, and R0 resection were 29%, 52%, 71%, 97%, and 98%, respectively, with a 1‐year recurrence rate of 12%. Conclusion NCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1759-7714 1759-7706 |
Relation: | https://doaj.org/toc/1759-7706; https://doaj.org/toc/1759-7714 |
DOI: | 10.1111/1759-7714.15291 |
URL الوصول: | https://doaj.org/article/28952c6dc5f84d36b302c89a16803ffd |
رقم الأكسشن: | edsdoj.28952c6dc5f84d36b302c89a16803ffd |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 17597714 17597706 |
---|---|
DOI: | 10.1111/1759-7714.15291 |